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Summary 
For over 25 years, the cytokine known as macrophage migration inhibitory factor (MIF) has 
been considered to be a product of activated T lymphocytes. We recently identified the murine 
homolog of human MIF  as  a  protein  secreted by  the pituitary in  response  to  endotoxin 
administration.  In the course of these studies, we also detected MIF in acute sera obtained from 
endotoxin-treated, T  cdl-defident (nude), and hypophysectomized mice, suggesting that still 
more cell types produce MIE Here, we report that ceils of the monocyte/macrophage lineage 
are an important source of MIF in vitro and in vivo. We observed high levels of both preformed 
MIF protein and MIF mRNA in resting,  nonstimulated cells. In the murine macrophage cell 
line RAW 264.7, MIF secretion was induced by as little as 10 pg/ml of lipopolysaccharide (LPS), 
peaked at 1 ng/ml, and was undetectable at LPS concentrations >1/~g/ml. A similar stimulation 
profile was observed in LPS-treated peritoneal macrophages; however, higher LPS concentrations 
were necessary to induce peak MIF production unless cells had been preincubated with interferon 
3, (IFN-'y).  In RAW 264.7 macrophages, MIF secretion also was induced by tumor necrosis 
factor  oe (TNF-c  0  and IFN-% but not by interleukins  1 B or 6.  Of note,  MIF-stimulated 
macrophages were observed to secrete bioactive TNF-cz. Although previously overlooked, the 
macrophage is both an important source and an important target of MIF in vivo. The activation 
of  both central (pituitary) and peripheral (macrophage) sources of MIF production by inflammatory 
stimuli provides further evidence for the critical role of this cytokine in the systemic response 
to tissue invasion. 
N 
'umerous observations over the years indicate that the 
hypothalamic-pituitary-adrenal  axis is essential in the 
normal host response to infection and tissue invasion (1-4). 
In the course of investigating the role of the pituitary in sys- 
temic inflammatory responses,  we identified  the  murine 
homolog of human macrophage migration inhibitory factor 
(MIF) 1 as a protein secreted by the anterior pituitary in re- 
sponse to LPS stimulation (5). Pituitary MIF was found to 
contribute to the MIF present in plasma in the postacute phase 
(>2 h) of endotoxemia. Recombinant murine MIF markedly 
increased lethality when coinjected with LPS, and anti-MIF 
antibody conferred full protection against lethal endotoxemia, 
suggesting that MIF is an important and possibly  critical medi- 
ator of endotoxic shock. 
Historically,  MIF has been considered a product of acti- 
vated T  lymphocytes and appears to exhibit  a number of 
1 Abbreviations used in this ~per: FBS, fetal  bovine  serum;  MIF, macrophage 
migration inhibitory  factor. 
macrophage-activating  properties (6-12). While studying MIF 
production in experimental  endotoxemia,  however, we de- 
tected MIF in acute sera obtained from LPS-injected, T cell- 
deficient (nude), and hypophysectomized mice, suggesting 
that yet additional cell types may produce MIF in vivo. Since 
the macrophage is a major source of the cytokines that ap- 
pear in response to LPS administration (13), we examined 
the possibility that MIF also is produced by cells of the mono- 
cyte/macrophage lineage. 
In this study, we report that monocytes/macrophages syn- 
thesize and release MIF after stimulation with LPS, TNF-o~, 
and IFN-q/. In contrast to previously studied macrophage- 
derived cytoldnes, both MIF protein and mRNA are present 
in substantial, preformed amounts in these cells. Moreover, 
stimulation ofmacrophages with recombinant MIF induced 
the secretion of significant amounts of TNF-cz, suggesting 
that these two cytokines may act together in a proinflamma- 
tory loop. Although previously overlooked, we conclude that 
the macrophage is not only a cellular target of T cell or pitu- 
itary MIF but also is an important source of MIF production 
in vivo. 
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Reagents.  Escherichia coil Olll:B4  LPS, polymyxin B,  car- 
benicillin, PMSF, and Tween-20 were obtained from Sigma Chem- 
ical Co. (St. Louis, MO). LPS was resuspended in pyrogen-free 
water, vortexed, sonicated, aliquoted (5 mg/ml), and stored at 
- 20"C. Serial  dilutions of  LPS were prepared in pyrogen-free  water 
by sonication (model 3210; Branson Ultrasonics Corp., Danbury, 
CT). C-entamicin was from GIBCO BILL (Gaithersburg, ME)). 
Thioglycollate broth (Difco, Detroit, MI) was prepared according 
to the manufacturer's recommendation, autoclaved, and stored 
protected from light at room temperature. Horseradish peroxi- 
dase-conjugated goat anti-rabbit  antibody was purchased from 
Pierce (Rockford,  IL) and 4-chloro-l-naphthol  and stabilized  3,Y,5,5'- 
tetramethylbenzidene (TMB) substrate for horseradish peroxidase 
were from Promega Corp. (Madison, WI). Polyclonal anti-MIF 
serum was generated by immunizing New Zealand White rabbits 
(Hare Marland, Hewitt, NJ) with purified recombinant murine 
MIF (rMIF). At weeks I and 2, rabbits were inoculated intrader- 
mally with 100 ~g of rMIF diluted in CFA, and with 50/~g of 
rMIF diluted in IFA on week 4. Immune serum was collected 
1 wk after the last inoculation. 
Cytokines.  rMIF was expressed  in E. coil BL21/DE3 (Novagen, 
Madison, WI) (5) and purified to homogeneity by anion exchange 
(Mono Q; Pharmacia, Piscataway, NJ) and reverse phase chroma- 
tography (CS-SepPak; Millipore  Corp., Milford, MA), lyophilized, 
and reconstituted in sodium phosphate buffer (20 mM, pH 7.2) 
following procedures to be reported dsewhere  (Bernhagen, J., 
R. A. Mitchell,  T. Cahndra, W. Voelter, A. Cenmi, and R. Bucala, 
manuscript submitted for publication). MIF bioactivity was estab- 
lished by measuring dose-dependent, MIF-induced augmentation 
of Leishmania major killing by macrophages and by neutralization 
of  this activity with anti-MIF antibody (Gessner, A., Personal  com- 
munication), rMIF contained 9 pg of endotoxin per microgram 
of protein as determined by the chromogenic Limulus amoebocyte 
assay (BioWhittaker, Inc., Walkersville, MD). Recombinant mu- 
fine TNF-cx was a generous gift from Dr. Michael  Paladino (Genen- 
tech, San Francisco, CA). Recombinant marine Ibl/3 and lI~ (5 
/xg/ml after reconstitution) were obtained from R&D Systems,  Inc. 
(Minneapolis, MN) and recombinant routine IFN-~/(10  s IU/ml) 
was from Boehringer  Mannheim (Indianapolis,  IN). Cytokines  were 
reconstituted in pyrogen-free water containing 0.1% of very low 
endotuxin BSA (Miles, Inc., Kankakee,  IL) and stored at -80~ 
The endotoxin content of the reconstituted  cytokines  was 0.5 ng/#g 
of TNF-c~, 2 ng//~g of ID1B, 1.1 ng//~g of II.-6, and 0.6 pg/U 
of IFN-~/as determined by the chromogenic Limulus amoebocyte 
assay. 
Animals and Experimental Design.  8-10-wk-old  (19-21 g) female 
BALB/c (control), T cell-defident  BALB/c  "u/"u (nude), and hy- 
pophysectomized  BALB/c  mice were purchased from Charles River 
Labs. (Kingston, NY). Animals were housed in groups of 5 or 10 
mice Per cage with free access to food and water (supplemented 
with 5% glucose for hypophysectomized  mice) and were acclima- 
tized  for  5 d  before experimentation.  Mice were injected in- 
traperitoneally  with nonlethal doses  of  LPS (2.25 mg/kg for BALB/c 
and T cell-deficient mice and 50/~g/kg for hypophysectomized 
mice), and killed 2, 8, and 20 h after LPS challenge  to collect  serum. 
The LPS dose was adjusted to provide comparable  lethality in the 
control BALB/c group as among the hypophysectomized mice, 
which are hypersensitive  to endotoxin (4). 5 #1 of serum was ana- 
lyzed by Western blotting and visualized with anti-MIF antibody 
as described below. 
Organ Distribution of Murine MIF Protein.  The organ distribu- 
tion of  MIF protein was examined  in a 8-10-wk-old female  BALB/c 
mouse killed by CO2 asphyxiation and necropsied under aseptic 
conditions. Organs (brain, liver, spleen, ldchaeTs,  adrenals, and lungs) 
were excised, sectioned,  and homogenized  at 4~  with Tris-b~ 
saline (50 mM Tris-Base, 150 mM NaCl, pH 7.5) containing 1% 
NP-40, 0.5% denxycholic  add, 0.1% SDS, 2 mM EDTA, and I mM 
PMSE Cellular debris was pelleted and aliquots of organ lysate su- 
pernatants, adjusted for protein concentration, were diluted with 
an equal volume of redudng SDS-PAGE sample buffer. Samples 
(equivalent to 60/~g of  protein) were electrophoresed  through 18% 
polyacrylamide  gels and transferred to nitrocellulose membranes 
for Western blot analysis using polyclonal anti-MIF serum. 
Cells.  RAW 264.7 routine macrophages, THP-1 human mono- 
cytes, ASI.-1 routine and  Jurkat human T lymphocyte  cell  lines were 
obtained from the American Type Culture Collection (Kockville, 
MD). Cells were grown in RPM11640 medium (Gibco BILL)  con- 
taining 2 mM glutamine, 10% heat-inactivated  fetal bovine serum 
(FBS) (HyClone Labs., Logan, UT), and 50/~g/ml of  carbenicillin 
and gentamicin. Medium for ASD1 cells was supplemented with 
1 mM sodium pyruvate. Thioglycollate-elicited  peritoneal macro- 
phages were obtained from BALB/c mice that were injected in- 
traperitoneally 3-4 d previously  with 2 ml of sterile thioglycollate 
broth. Cells were harvested under strict aseptic conditions by la- 
vage of the peritoneal cavity with 5 ml of an ice-chilled 11.6% 
sucrose solution. After centrifugation for 10 min at 800 g, cells 
were resuspended in KPMI/10% FBS, enumerated, and plated at 
a density of 2  x  106 or 4  x  106 cells/well. Human PMN were 
isolated from peripheral blood by density gradient centrifugation 
as previously described (14, 15). 
MIF Content of  Macrophage and T Lymphocyte Lysates.  Aliquots 
of 106 cells of each type were lysed with Tris-buffered  saline con- 
taining 1% NP-40, 0.5% denxycholic  add, 0.1% SDS and 2 mM 
EDTA. Cellular  debris was Pelleted  and the supematants  were diluted 
with an equal volume of reducing SDS-PAGE sample buffer. 10 
/~1 of lysate (equivalent to 5  ￿  l& ceUs) was electrophoresed 
through 18% polyacrylamide  gds and transferred to nitrocelhlose 
membranes for Western blot analysis  using polyclonal  rabbit anti- 
MIF serum. 
Stimulation of Macrophages by LPS and Cytokines.  RAW 264.7 
macrophages were washed with fresh medium, harvested  by gentle 
scraping, resuspended in R.PMI/10% FBS, and incubated at 2  x 
106 or 4  x  10  ~ cells/well in 3.5-cm tissue culture phtes (Linbro| 
Flow Laboratories, McLean, VA). After 3 h of incubation at 37"C 
in a humidified atmosphere with 5% COz, nonadherent cells were 
removed and wells were washed twice with R.PMI/1% FBS. Ceils 
then were incubated for 12 h with LPS (at concentrations ranging 
from 1 pg/ml to 10 #g/ml) or with cytokines (1 or 10 ng/ml for 
TNF-a, IblB, and IL-6, and 10, 100, or 1,000 IU/ml for IFN-'y) 
diluted in R.PMI/1% FBS. For time course experiments, condi- 
tioned media of parallel cultures were removed at 3-, 6-, 9-, 12-, 
and 15-h intervals  after LPS stimulation.  Thioglycolhte-elicited  peri- 
toneal macrophages (107 cells/weU) were harvested as described and 
conditioned similarly to RAW 264.7 cells. Cells were incubated 
for 12 h with either LPS or IFN-3r plus LPS. When costimulated 
with IFN-'/and LPS, ceUs were first incubated for 1 h with IFN-3, 
(100 IU/ml) before addition of  LPS at the indicated  concentrations. 
At the end of each experiment, cell culture media were collected, 
centrifuged for 10 min at 800 g, and supplemented with PMSF 
(1 raM). Supernatants then were concentrated 10-fold by mem- 
brane filtration (10kD cut-ofi~ (Centricon-10; Amicon, Beverly, 
MA). Cellular KNA was extracted from adherent cells as described 
below. 
RNA Extraction  and lsolation  of  MIF mRNA by Reverse Transcription 
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extracted  from macrophages  with RNAzoI-B (Tel-Test  Inc., Friends- 
wood, TX) following the manufacturer's protocol. 1 ~tg of RNA 
was reversed transcribed using oligo (dT)~,ls and M-MLV reverse 
transcriptase (GIBCO BRL) in a 50 ~tl reaction. 5/zl of cDNA 
was amplified by PCR in a thermal cycler (model 9600; Perkin- 
Ehner/Cetus, Norwalk, CT) (denaturation for 1 rain at 94~  an- 
nealing for I min at 55~  and elongation for I rain at 72~  using 
mutine M1F primers 0 2 cycles),  TNF primers (22 cycles),  or fl-actin 
primers (25  cycles). Murine  intron-spanning  MIF and B-actin 
primers have been reported dsewhere (5). Intron-spanning TNF 
primers were 5'-GCGGAGTCC~AGG'ICTA-Y and 3'-GGC- 
GGC~TGGCTCTGTGAGG-5'.  DNA amplification  products were 
analyzed on 2% agarose gels and gel loading was normalized to 
B-actin PCR products. Quantification of MIF mRNA from LPS- 
stimulated  RAW 264.7 macrophages  was done by competitive  PCR 
as described (5, 16). The 273-bp competitive cDNA template was 
added at the indicated concentrations and coamplified with MIF 
cDNA using MIF primers. 
Western Blots.  For Western blotting, samples were resolved on 
18% SDS polyacrylamide  gels under reducing conditions and trans- 
ferred onto nitrocellulose membrane (Schleicher & Schuell, Inc., 
Keene, NH) at 50 V and 150 mA for 16 h. Membranes  were blocked 
with 500 mM NaCI, 50 raM Tris-Base, pH 7.5, buffer containing 
5% nonfat dry milk and 0.05% Tween-20 and incubated first with 
polyclonal rabbit anti-rMIF serum and then with horseradish per- 
oxidase--conjugated goat anti-rabbit  IgG antibody (each diluted 
1:1,000 in 500 mM NaCI, 50 mM Tris-Base, pH 7.5 buffer with 
1% BSA and 0.05% Tween-20). Polyclonal  rabbit anti-murine MIF 
serum was demonstrated to react with both natural and recom- 
binant murine and human MIF. Incubations were for 1 h each. 
MIF was visualized by development with chloronaphthol/H202 
or with TMB substrate, Serum MIF bands were quantified by laser 
densitometry (model CS-90~U; Shimadzu Corp., Braintree, MA) 
(17). Faint densitometric signals in the MIF region were detected 
in most sera before LPS administration (0 h). Hence, scanning in- 
tegrals are presented as relative serum MII: content (i.e., fold in- 
crease) normalized to the respective 0 h zone (i~., background or 
baseline stalnir~g)  on each membrane.  Each plotted point is the mean 
_+  SEM of individual sera from two to five animals. To further 
quantify the amount of circulating MIF after LPS administration 
in vivo, serum MIF bands were compared and quantitated relative 
to rMIF standards electrophoresed on the same SDS gels. Calcu- 
lated estimates  of serum MIP concentrations  were expressed  as molar 
concentrations. 
MltZinduced Secretion of TNF by RAW 264.7 Macrophagex  Cells 
(4  x  106/well)  were processed as described above and stimulated 
for 12 h with rMIF at specified  concentrations ranging from 100 
pg/ml to 1/zg/ml. At 1/zg/ml of rMIF, LPS contamination was 
9 pg/ml as assessed by Liraulus assay. To neutralize this minute 
amount ofLPS, rMIF was preincubated for 1 h at 37~  with poly- 
myxin B (1/~g/ral). MIl~-induced  TNF activity in cell culture su- 
Pernatant was quantitated by L929 cell cytotoxicity as described 
previously  (18). MIF-induced  TNF activity was blocked  completely 
by anti-TNF antibodies, rMIF did not contribute to TNF activity, 
as recombinant routine TNF (dose range, 5 pg/ml-1/zg/ml) cyto- 
toxicity remained unchanged when rMIF (10 pg/ml-10/zg/ml) or 
anti-MIF polyclonal serum was added to L929 cells together with 
rTNF. 
Results 
Serum  MIF  Levels  in  LPS-injected  Mice.  We  recently 
reported that pituitary MIF contributes significantly to the 
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MIF that appears in serum during endotoxemia. Serum MIF 
reached peak levels in normal mice at 20 h but was undetect- 
able in hypophysectomized  mice at this time, suggesting that 
the pituitary is a major source of the MIF that appears in 
serum after LPS injection (5). 
The central role played by MIF in endotoxic shock, to- 
gether with the known h~sitivity  of  hypophysectomized 
mice to LPS, led us to examine more dosdy the kinetics of 
MIF appearance in the circulation during the early, acute phase 
(i.e., 2-8 h) of endotoxemic shock. For purposes of compar- 
ison, we also examined serum MIF kinetics in nude mice, 
which lack a T  cell  source of MIE  Control,  hypophysec- 
tomized, and nude mice were injected with LPS and serum 
prepared at intervals and quantified for MIF content by Western 
blotting and laser scanning densitometry (Fig.  1). Whereas 
serum MIF concentrations increased  gradually over 20 h in 
control mice, hypophysectomizeed  mice exhibited a rapid rise 
and then prompt fall in MIP that peaked 2 h after LPS injec- 
tion. In nude mice, the rise in serum MIP was delayed by 
8-12 h, but increased  in a manner that was similar to that 
of the control mice. Peak serum MIF concentrations were 
compared and quantitated relative to rMIF standards electro- 
phoresed and transferred on the same nitrocellulose mem- 
brane.  Estimates of peak  serum  MIF in  the different ex- 
perimental groups  were  calculated to be  in  the  range  of 
30-60  riM. 
Given  the  lack  of  a  pituitary  source  of  MIF  in  the 
hypophysectomized  mice, we considered that the MIF present 
in the circulation at 2 h  must reflect the release of MIF by 
an additional LPS-sensitive cell population. Such serum MIF 
kinetics were reminiscent of a macrophage TNF response 
(19-21)  and we next examined the possibility that MIF is 
produced by cells of the monocyte/macrophage lineage. 
Figure  1.  Western  blotting and densitometric  analysis  of serum MIF 
in BALB/c, BALB/c  ."/..,  and hypophysectomized  BALB/c mice. Mice 
were injected  intraperitoneally  with LPS and blood sampled  at intervals 
for Western  blotting  analysis  as described  in Materials  and Methods.  The 
content of  MIF in serum  aliquots  (5 #1) was quantified  by laser  densitom- 
etry with reference  to electrophoresed  rMIP standards. (Inset) MIF blot 
for the BALB/c  mice, demonstrating  the time-depend~t  increase  in serum 
MIF after LPS administration.  Each plotted point is the mean _+ SEM 
of individual sera from two to five animals. Expression of MIF in Resting Macrophages and Mouse Tis- 
sues.  Since both a pituitary cell line (AtT-20) and the whole 
pituitary in vivo contain substantial amounts of preformed 
MIF (5), we first analyzed the intracellular MIF content of 
various inflammatory  cells and cell lines. Significant amounts 
of preformed MIF protein were found to be present in cell 
lysates obtained from resting, nonstimulated murine RAW 
264.7 cells, murine peritoneal macrophageg and human THP-1 
monocytes (Fig. 2 A). We estimate that on average there is 
0.1-1 pg of immunoreactive,  preformed  MIF protein per mac- 
rophage.  The MIF  content of murine or  human mono- 
cytes/macrophages was similar to that of two T  cell lines, 
the human Jurkat and the marine ASL-1. In contrast, cell 
lysates obtained from purified PMN exhibited no detectable 
MIF protein (Fig.  2 A). 
We then examined the organ distribution of MIF protein 
in normal mice. Mouse tissues were homogenized and ali- 
quots of total protein dectrophoresed  and analyzed by Western 
blotting. As shown in Fig. 2 B, preformed MIF was detect- 
able in mouse liver, spleen, kidney, and brain. These organs 
con~n significant amounts of macrophages, suggesting that 
the MIF protein present in these tissues is at least partly mac- 
rophage associated. 
MIF Secretion  by LPS-stiraulated  Macrophages.  MIF was ob- 
served to be secreted by macrophages into culture medium 
after LPS stimulation (Fig. 3). In RAW 264.7 macrophages, 
Figure  2.  (A) Western blot analysis of the MIF content of nonstimu- 
luted monocytes/macrophages, T-lymphocytes,  and PMN.  10 #1 of cell 
lysate (equivalent  to 5  x  103 cells) were electrophoresed  through  18% 
gels, transferred to nitrocellulose membrane, and analyzed with anti-MIF 
polyclonal antibody. 30 ng of rMIF was electrophoresed and transferred 
as a standard. (B) Western blot analysis of the organ distribution of rou- 
tine MIF protein. Organs were obtained from an untreated BALB/c mouse 
and prepared as described in Materials and Methods. Aliquots (60 #g of 
protein) of liver, spleen, kidney, and adrenal, brain, and lung lysates were 
eleetrophoresed through 18% gels, transferred to nitrocellulose membrane, 
and analyzed with anti-MIF polyclonal  antibody. 20 ng of rMIF was dec- 
trophoresed and transferred  as a standard.  Although not visible, a MIF 
band of much lower intensity also was detected in the adrenals and lungs. 
Figure  3.  Western blot analysis of MIF secretion by RAW 264.7 cells 
(.4) and by thioglycoNate-elicited peritoneal macrophages stimuhted with 
LPS (B) or with IFN--/plus LPS (C'). Macrophages (4 x  106 RAW 264.7 
cells or 107 peritoneal macrophages)  were incubated for 12 h with LPS 
or IFN~ plus LPS at the indicated concentrations. The content of MIF 
secreted into the medium was analyzed by Western blotting as described 
in Materials and Methods. rMIF (30 ng in A  and 20 ng in B and C) was 
electrophoresed  and transferred  as a standard. 
MIF secretion was induced by as little as 10 pg/ml of LPS, 
peaked at 1 ng/ml, and was not detectable at LPS concentra- 
tions >1/~g/ml (Fig. 3 A). In elicited peritoneal macrophages, 
1 ng/ml of LPS was required to induce MIF secretion, and 
a maximal response was observed with 10-100 ng/ml of LPS 
(Fig. 3 B). Of significance, costimulation of cells with IFN-'y 
(100 IU/ml, given 1 h before LPS) plus LPS resulted in a 
>1,000-fold increase in LPS responsiveness  (Fig.  3 C). 
We next examined the time course of MIF secretion in 
parallel cultures of RAW 264.7 macrophages maximally stimu- 
lated with 1 ng/ml of LPS. As assessed by Western blotting, 
MIF was first detected 6-9 h  after LPS stimulation. Max- 
imum amounts of MIF appeared in medium between 9 and 
12 h after LPS stimulation (Fig. 4). MIF levels then decreased, 
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macrophages.  Parallel cultures  (4  x  106 cells) were incubated  with  1 
ng/ml of LPS and the conditioned medium removed at 3-h intervals for 
Western blot analysis of MIF content. 20 ng of rMIF was dectrophoresed 
and transferred as a standard. 
indicating that after 12 h, MIF is degraded at a rate that ex- 
ceeds that of synthesis and release by macrophages. 
Expression  of  MlF mRNA by LPS-stirnulged  Macrop~gez  The 
expression of MIF mRNA by LPS-stimulated RAW 264.7 
macrophages was investigated by RT-PCR. Parallel cultures 
were incubated for 12 h with medium or increasing amounts 
of LPS and analyzed for the expression of MIF, TNF-a, and 
/3-actin. MIF mRNA was expressed constitutively in non- 
stimulated murine RAW 264.7 (Fig. 5) and in didted peri- 
toneal macrophages (data not shown). As expected, the ex- 
pression  of  TNF-oe  increased  over  the  range  of  LPS 
concentrations (1 pg/ml-1 #g/m1). In contrast, MIF mKNA 
levels  correlated  inversely  with  LPS  concentration.  MIF 
mRNA level was highest in calls induced with 1 pg/ml of 
LPS and lowest in those induced by 1 #g/ml of LPS. 
To assess  more quantitatively the induction ofMIF mKNA, 
cDNA was prepared from control and LPS-stimulated cul- 
tures of RAW 264.7 macrophages and analyzed by competi- 
tive PCR. The amount of competitive template that was re- 
quired to obtain equivalent levels  of  MIF and competitor  DNA 
amplification products was  1.5 pg for nonstimulated (con- 
trol) macrophages and 3  pg for LPS-induced (100 pg/ml) 
RAW 264.7 macrophages (Fig. 6). Therefore, macrophage 
MIF mRNA increased approximately twofold after LPS in- 
duction, a level comparable to that observed in pituitary cells 
in vivo (threefold after induction with 45 #g of LPS injected 
intraperitoneally) (5). We next examined the time course of 
MIF mRNA in RAW 264.7 macrophages incubated with 
1 ng/ml of LPS, the LPS concentration that induced max- 
Figure 5.  RT-PCR analysis of MIP, TNF-a, and/3-actin expression 
by LPS-stimuhted RAW 264.7 macrophages. Cells (4  x  106) were in- 
cubated for 12 h in medium containing KPMI/1% FBS and LPS at the 
indicated concentrations. Total cellular KNA was extracted, cDNA pre- 
pared, and gene-specific  PCR products analyzed by agarose gel dectropho- 
resis as described in Materials and Methods. 
imum MIF secretion in these cells (see Fig. 3). MIF mRNA 
levels increased 6 h after LPS induction and remained devated 
for up to  12 h  after LPS induction (data  not shown). 
Interaction between  MIF and Proinflammatory  Cytokines.  The 
detection of elevated levels of MIF in blood after LPS ad- 
ministration (Fig. 1) together with the finding of an impor- 
tant role for MIF in experimental endotoxemia (5) led us to 
investigate the interaction between MIF and other proinflam- 
matory cytokines. We first studied MIF secretion by RAW 
264.7  macrophages stimulated with  recombinant murine 
TNF-c~, IL-1/$, IL-6, or IFN-% By Western blotting, TNF-ot 
and IFN-T were found to induce MIF secretion in a dose- 
dependent fashion (Fig.  7).  The lowest  concentration of 
cytokine that was effective under these experimental condi- 
tions was 1 ng/ml of TNF-c~ and 10 IU/ml of IFN-% The 
TNF-o~ and IFN-  7 effects could not be accounted for by LPS 
contamination of recombinant cytokine preparations, which 
were found to be 0.5 pg/ng of TNF-o~ and 60 fg/U of IFN~. 
LPS and 1FN~y had an additive/synergistic effect on MIF secre- 
tion, whereas TNF-a and IL-1/3 did not (data not shown). 
Finally, MIF production was not induced by either IL-1/3 
or IL-6 at  1 or  10 ng/ml. 
We then examined the secretion of TNF-c~ and IL-1/3 by 
RAW 264.7 macrophages stimulated  with rMIF. MIF samples 
were preincubated for 1 h with polymyxin B at 1 #g/ml to 
neutralize small amounts of contaminating LPS (9 pg//zg of 
MIF by the chromogenic Limulus assay), rMIF at concentra- 
tions ~100 ng/ml was found to induce the secretion of bi- 
oactive TNF-a as determined  by the L929 cytotoxidty assay 
(Fig. 8). The MIF-induced TNF bioactivity was blocked com- 
pletely by anti-TNF antibodies and rMIF did not contribute 
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Figure 6.  Competitive  PCR  analysis of 
macrophage MIF raRNA after LP$ stimula- 
tion. RAW 264.7  cells (4  x  10~) were in- 
cubated for 12 h in RPMI/1% FBS with or 
without  LPS (100  pg/ml).  KNA was extracted 
and MIF mRNA levels analyzed as described 
in Materials and Methods. The amount of  MIF 
competitor template DNA ranged from 0.25 
to 15 pg per reaction  as shown. Figure 7.  Western blot analysis ofcytokin~induced  MIF secretion by 
RAW 264.7 macrophages. Cells (4  ￿  106) were incubated for 12 h with 
TNF-ot, Ibl~, II.-6 (10 or 1 ng/mi), or IFN-3r (1,000 or 100 IU/ml). 
20 ng of rMIF was electrophoresed and transferred as a standard. 
to TNF cytotoxicity, as recombinant murine TNF cytotox- 
icity was unchanged  when rMIF or anti-MIF polydonal serum 
was ~dc~l to L929 cells together with ffNF (data not shown). 
IL-1/3 secretion, in contrast, was not detectable by Western 
blotting over the concentration of rMIF tested. 
MIF was described originally as a T lymphocyte-associated 
activity that inhibited the random migration of guinea pig 
peritoneal macrophages (6, 7). Over the years, MIF activity 
was reported to be associated with delayed-type hypersensi- 
tivity (6, 7), to be produced by lectin-activated T  cells, and 
to enhance macrophage adherence, phagocytosis (8, 9), and 
tumoriddal activity (10). Nevertheless, the biological activi- 
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Figure 8.  Concentration of  TNF~ in cell culture supematants of RAW 
264.7 maczophages stimulated with rMIF. Ceils (4  x  106)  were incubated 
for 12 h with the indicated concentrations of rMIF or with medium alone 
(control).  Culture medium then was removed and the TNF-a content 
quantified by L929 cell cytotoxicity. TNF-a concentration is expressed 
as the difference  between the level produced by rMIF-stiraulated cells and 
by control (nonstimulated)  cells. Data are expressed as the mean +  SD 
of three  separate experiments. 
ties attributed to MIF remained ambiguous, as these studies 
were performed with lymphocyte  culture supernatants which 
were shown subsequently to contain other cytokines with 
MIF activity,  such as IFN-'y and IL-4 (22-24). More recent 
experiments conducted with rMIF suggest that MIF in fact 
activates monocytes/macrophage to kill Leishmania donovani 
(Gessner, A., personal communication) and tumor cells (12). 
We recently isolated and cloned the routine homolog of 
human MIF after identifying its release by the pituitary in 
response to LPS administration. Pituitary MIF was found to 
contribute to circulating MIF levels after endotoxemia and 
exogenous  MIF  increased  markedly  the  lethality  of  ex- 
perimental endotoxemia in mice (5). In this study, we sought 
to identify additional cellular sources of MIF. MIF was de- 
tected in the blood of LPS-challenged, T cell-deficient, and 
hypophysectomized  mice suggesting that, in addition to the 
T cell and the pituicyte, other cell types contribute to MIF 
production in vivo. The extremely rapid rise in serum MIF 
which occurred in hypophysectomized  mice further suggested 
to us a response that could be attributed to an LPS-sensitive 
immune cell such as the monocyte/macrophage. 
Although previously unsuspected, we found that macro- 
phages are an important source of MIF production in vivo. 
Resting,  nonstimulated  RAW  264.7  macrophages  and 
thioglycollate-dicited  peritoneal macrophages contain abun- 
dant quantities of preformed MIF. MIF protein was detected 
in normal mouse fiver, spleen, kidney, and brain. Much lower 
amounts of MIF also were found in the adrenals and lungs. 
These data are consistent with recent studies reporting the 
presence of MIF mRNA in various tumor cells and tissues 
(25, 26). We detected MIF protein in macrophage-rich  organs 
such as liver, spleen, brain, or kidney, suggesting that the 
MIF present in various tissues may be at least partly macro- 
phage associated. 
Various proinflammatory stimuli, such as LPS, TNF-ol, 
and IFN-~/were observed to be potent inducers of macro- 
phage MIF secretion. Secretion of significant amounts of  MIF 
occurred at rehtively low LPS concentrations (10-100 pg/ml), 
suggesting that macrophage-derived MIF is likely to be released 
in patients with gram-negative bacterial infections (27-29). 
Surprisingly, MIF secretion by RAW 264.7 macrophages, and 
to a lesser extent by peritoneal macrophages, decreased at high 
concentration of LPS (1-10/~g/ml). Analysis of the expres- 
sion of MIF mB.NA yielded similar results, as MIF mRNA 
levels decreased markedly with increasing LPS concentrations 
(>0.1 ng/ml of LPS). This contrasts with the macrophage 
TNF response where expression of both TNF protein and 
mlLNA increased in a dose-dependent  fashion. Possible mech- 
anisms for the apparent downregulation of MIF at high LPS 
concentration are not immediately evident. Neverthdess, the 
relatively low leeds of LPS which initiate this dowuregula- 
tion suggests that a similar downregulatory response is likely 
to occur in vivo as well. 
The net concentration of MIF in supernatants of macro- 
phage cultures peaked about 12 h after LPS stimulation. In 
vivo, however, elevated serum levels of MIF were detected 
as early as 2 h after LPS administration and increased in a 
1900  Macrophage Production of Migration Inhibitory Factor time-dependent manner. MIF levels were nearly maximal 8 h 
after LPS administration  and plateaued thereafter.  In hypo- 
physectomized mice, serum MIF levels peaked 2 h after LPS 
injection.  The mechanism responsible for this rapid rise in 
serum  MIF is unknown,  but may be related  to the well- 
described hypersensitivity of hypophysectomized animals to 
LPS (4). In contrast, the appearance of serum MIF was delayed 
in T cell-defident mice, suggesting that T  cells either con- 
tribute directly to the early rise of serum MIF, or act indirectly 
by releasing cytokines such as TNF-oe or IFN-'I/that  then 
promote the release  of macrophage MIF. 
Indeed, TNF-c~ and IFN-7 but not IL-1/~ and IL-6 were 
found to be potent inducers of MIF secretion by macrophages 
in vitro. Of importance, rMIF also was found to induce TNF 
secretion by macrophages, suggesting that MIF and TNF may 
act together to augment acute, proinflammatory responses. 
In the situation of a severe infection however, the proinflamma- 
tory effects of MIF may be detrimental as indicated by our 
recent findings that MIF markedly increased lethality when 
coinjected with LPS, whereas anti-MIF antibody prevented 
LPS lethality. These data also suggest that in extreme situa- 
tions  such as septic shock,  MIF,  like TNF,  may be over- 
produced, and neutralization of either cytokine can be shown 
to fully protect against the toxicity of endotoxin administra- 
tion  (5,  30--33). 
The production of MIF by LPS-stimulated macrophages 
indicates that this cytokine may serve an important  role in 
acute inflammatory responses. Taken together with the finding 
that MIF is a major protein constituent of the pituitary that 
is released during endotoxemia, this study supports the con- 
cept that MIF plays a systemic, regulatory function in host 
immunity. Macrophage MIF, once released by a proinflamma- 
tory stimulus,  may act in concert with TNF-ot and other 
cytokines to coordinate host defenses against infection or tissue 
invasion. Pituitary MIF, on the other hand, may serve to prime 
systemic immune responses once a localized inflammatory site 
fails to contain an invasive agent, or rise act as a central nervous 
system--derived stress signal to activate the immune system 
in anticipation  of an impending,  invasive  stimulus.  Studies 
are in progress to delineate the role of pituitary, macrophage, 
and T cell MIF in acute and chronic inflammatory conditions. 
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